VG Life Sciences Inc. (VGLS)

[tradernewstip]

$VGLS The Company is engaged in developing transformative therapies to treat drug-resistant cancers, infectious diseases and autoimmune diseases caused by chronic inflammation. The Company operates as a drug discovery and development company researching two core technologies: Targeted Peptide Technology (TPT) and Metabolic Disruption Technology (MDT). The Company's MDT compounds impede tumor cells' ability to meet their energy requirements, leaving cancer cells vulnerable to cancer-killing agents. Its autoimmune therapy, TPT, eliminates a subpopulation of pro-inflammatory immune cells and presents a possible treatment for autoimmune and infectious diseases. Its peptides are designed to function in all Major Histocompatibility Complex II (MHC-II) phenotypes. It also has a drug research program in pre-clinical stages, a TPT therapy for human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) using VG1177.